The US market for interventional oncology devices continues to grow, driven by expanding treatable patient populations and increasing uptake of premium-priced technology. However, growth in this market will be hindered to some extent by mixed clinical data, which has somewhat deterred adoption of interventional oncology devices.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.


The dynamic patient population eligible for interventional oncology procedures supports growth in the ablation device and embolization particle markets.

How have approved indications changed in recent years?

What are the fastest growing patient populations eligible for interventional oncology treatments?

What is the clinical evidence supporting the use of ablation or embolization particles in various types of cancer?

Microwave ablation devices and niche technologies, such as IRE, are rising in popularity among interventional oncologists.

What are the advantages and disadvantages of each type of ablation device?

How does the uptake of microwave ablation and IRE devices affect other types of ablation devices?

In which indications will these newer ablation devices experience the fastest adoption?

How can companies in the fragmented microwave ablation market gain a competitive advantage?

Growth in the premium-priced embolization particle segments, such as the DEBs and radioembolization sphere spaces, has slowed in recent years.

What factors has contributed to the slowing growth in these markets?

What are challenges facing physicians and competitors in this space?

How has M&A activity shaped the competitive embolization particles market in recent years?

Table of contents

  • United States
    • Abstract
    • Executive Summary
      • Market Highlights
      • Competitive Highlights
      • Market Developments
      • End-User Insights
      • Key Report Updates
      • Procedures Covered
      • Products Covered
    • Version History
    • Interventional Oncology Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Clinical Data
        • Reimbursement
        • Mergers, Acquisitions, and Partnerships
        • Product Improvements and Innovations
        • Product Portfolio Management
        • Physician Training and Marketing
      • Market Developments
    • Ablation Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • Radiofrequency Ablation Devices
        • Microwave Ablation Devices
        • Cryoablation Devices
        • Irreversible Electroporation Ablation
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Clinical Data
        • Product Improvements and Innovations
    • Embolization Particle Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • PVA Particles
        • Microspheres
        • Drug-Eluting Beads
        • Radioembolization Spheres
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Mergers, Acquisitions, and Partnerships
        • Product Portfolio Management
        • Physician Training and Marketing
    • Appendix
      • Abbreviations
      • Bibliography

Author(s): Bishwjit Ghoshal, MBA

Bishwjit Ghoshal is a senior analyst within the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali. Follow Bishwjit on twitter: @Bishwjit_DRG


Related Reports

Interventional Oncology Devices | Medtech 360 | Market Insights | Japan

Despite short-term contraction caused by the ongoing COVID-19 pandemic, as well as delays in the availability of new technologies due to strict regu...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Asia Pacific

Despite the challenges posed by the ongoing COVID-19 pandemic, the Asia Pacific interventional oncology device market will see strong growth

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Europe

European interventional oncology device procedure volumes and revenues will grow moderately, driven by an expanding patient population, rising patient and physician awareness, improved reimburse...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Latin America

The Latin American interventional oncology device market will see moderate growth, driven by an increasing patient population, adoption of premium-priced devices, and the introduction of new dev...

View Details